# Effect of Ensifentrine Treatment on CAT Score

> **NCT06460493** · PHASE3 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 20 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Ensifentrine 3 mg twice daily

## Key facts

- **NCT ID:** NCT06460493
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-11
- **Primary completion:** 2024-11-26
- **Final completion:** 2024-12-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06460493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06460493, "Effect of Ensifentrine Treatment on CAT Score". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06460493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*